{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:05:51Z","timestamp":1786982751586,"version":"build-2736575974"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T00:00:00Z","timestamp":1678752000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T00:00:00Z","timestamp":1678752000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"National Health Committee"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1007\/s40256-023-00575-8","type":"journal-article","created":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T11:03:30Z","timestamp":1678791810000},"page":"301-310","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Characteristics and Trends in Clinical Trials of Cardiovascular Drugs in China from 2009 to 2021"],"prefix":"10.1007","volume":"23","author":[{"given":"Jun","family":"Hao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junrong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuangshi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weida","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sidong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,14]]},"reference":[{"issue":"6","key":"575_CR1","first-page":"553","volume":"37","author":"The Writing Committee of the Report on Cardiovascular Health and Diseases in China","year":"2022","unstructured":"The Writing Committee of the Report on Cardiovascular Health and Diseases in China. Report on Cardiovascular Health and Diseases in China 2021: an Updated Summary. Chin Circ J. 2022;37(6):553\u201378.","journal-title":"Chin Circ J"},{"issue":"15","key":"575_CR2","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1016\/j.jacc.2015.03.016","volume":"65","author":"CB Fordyce","year":"2015","unstructured":"Fordyce CB, Roe MT, Ahmad T, et al. Cardiovascular drug development: is it dead or just hibernating? J Am Coll Cardiol. 2015;65(15):1567\u201382.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"575_CR3","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1001\/jama.2013.282542","volume":"311","author":"LV Sacks","year":"2014","unstructured":"Sacks LV, Shamsuddin HH, Yasinskaya YI, Bouri K, Lanthier ML, Sherman RE. Scientific and regulatory reasons for delay and denial of FDA approval of initial applications for new drugs, 2000\u20132012. JAMA. 2014;311(4):378\u201384.","journal-title":"JAMA"},{"issue":"2","key":"575_CR4","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/clpt.2010.286","volume":"89","author":"KI Kaitin","year":"2011","unstructured":"Kaitin KI, DiMasi JA. Pharmaceutical innovation in the 21st century: new drug approvals in the first decade, 2000\u20132009. Clin Pharmacol Ther. 2011;89(2):183\u20138.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"575_CR5","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/S1470-2045(18)30865-9","volume":"20","author":"S Zhao","year":"2019","unstructured":"Zhao S, Lv C, Gong J, et al. Challenges in anticancer drug R&D in China. Lancet Oncol. 2019;20(2):183\u20136.","journal-title":"Lancet Oncol"},{"issue":"9","key":"575_CR6","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/nrclinonc.2017.10","volume":"14","author":"Q Zhou","year":"2017","unstructured":"Zhou Q, Chen XY, Yang ZM, Wu YL. The changing landscape of clinical trial and approval processes in China. Nat Rev Clin Oncol. 2017;14(9):577\u201383.","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"575_CR7","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/jebm.12203","volume":"9","author":"M Song","year":"2016","unstructured":"Song M, Guo H, Chen H, Hu H. Characteristics of anticancer drug studies registered on the Chinese Clinical Trial Registry (ChiCTR) from 2007 to 2015. J Evid Based Med. 2016;9(2):59\u201368.","journal-title":"J Evid Based Med"},{"issue":"11","key":"575_CR8","doi-asserted-by":"publisher","first-page":"e619","DOI":"10.1016\/S1470-2045(19)30491-7","volume":"20","author":"N Li","year":"2019","unstructured":"Li N, Huang HY, Wu DW, et al. Changes in clinical trials of cancer drugs in mainland China over the decade 2009\u201318: a systematic review. Lancet Oncol. 2019;20(11):e619\u201326.","journal-title":"Lancet Oncol"},{"issue":"2","key":"575_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.729","volume":"9","author":"X Liu","year":"2021","unstructured":"Liu X, Wu S, Sun J, et al. Changes in clinical trials of endocrine disorder and metabolism and nutrition disorder drugs in mainland China over 2010\u20132019. Pharmacol Res Perspect. 2021;9(2): e00729.","journal-title":"Pharmacol Res Perspect"},{"key":"575_CR10","doi-asserted-by":"crossref","unstructured":"Chen H, Zhou Y, Han X, Shi Y. The changing landscape of anti-lymphoma drug clinical trials in mainland China in the past 15 years (2005-2020): a systematic review. Lancet Reg Health Western Pac. 2021;8:100097.","DOI":"10.1016\/j.lanwpc.2021.100097"},{"key":"575_CR11","doi-asserted-by":"crossref","unstructured":"Zhong Q, Tao Y, Chen H, et al. The changing landscape of anti-lung cancer drug clinical trials in mainland China from 2005 to 2020. Lancet Reg Health Western Pac. 2021;11:100151.","DOI":"10.1016\/j.lanwpc.2021.100151"},{"key":"575_CR12","unstructured":"Opinions of the state council on reforming the examination and approval system for drugs and medical devices. 2015. http:\/\/www.gov.cn\/zhengce\/content\/2015-08\/18\/content_10101.htm. Accessed 2 Apr 2022."},{"key":"575_CR13","unstructured":"The national drug review and approval system reform work conference was held in Shanghai. 2015. http:\/\/www.gov.cn\/xinwen\/2015-08\/26\/content_2919889.htm. Accessed 2 Apr 2022."},{"key":"575_CR14","unstructured":"Announcement of the General Administration on the work plan for the reform of the registration of chemical drugs. 2016. https:\/\/www.nmpa.gov.cn\/yaopin\/ypggtg\/ypqtgg\/20160309151801706.html. Accessed 2 Apr 2022."},{"key":"575_CR15","unstructured":"Opinions on deepening the reform of the examination and approval system and encouraging the innovation of pharmaceutical medical devices. 2017. http:\/\/www.gov.cn\/zhengce\/2017-10\/08\/content_5230105.htm. Accessed 2 Apr 2022."},{"key":"575_CR16","unstructured":"Announcement of the State Drug Administration and the State Health Commission on optimizing the examination and approval of drug registration and examination 2018. https:\/\/www.nmpa.gov.cn\/xxgk\/ggtg\/qtggtg\/20180523110601517.html. Accessed 2 Apr 2022."},{"key":"575_CR17","unstructured":"Announcement of the State Drug Administration on adjusting the approval process for drug clinical trial evaluation. 2018. https:\/\/www.nmpa.gov.cn\/xxgk\/ggtg\/ywlchshyjgrdgg\/20180727172901286.html. Accessed 2 Apr 2022."},{"key":"575_CR18","unstructured":"Opinions on Priority Review and Approval of Registration Backlogs. 2016. https:\/\/www.nmpa.gov.cn\/xxgk\/fgwj\/gzwj\/gzwjyp\/20160226085101295.html. Accessed 2 Apr 2022."},{"key":"575_CR19","unstructured":"Opinions of Carrying out Consistent Evaluation of the Quality and Efficacy of Generic Drugs. 2016. http:\/\/www.gov.cn\/zhengce\/content\/2016-03\/05\/content_5049364.htm. Accessed 2 Apr 2022."},{"issue":"10166","key":"575_CR20","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","volume":"393","author":"TA Zelniker","year":"2019","unstructured":"Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393(10166):31\u20139.","journal-title":"Lancet"},{"issue":"24","key":"575_CR21","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295\u2013306.","journal-title":"N Engl J Med"},{"issue":"15","key":"575_CR22","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stefansson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436\u201346.","journal-title":"N Engl J Med"},{"issue":"15","key":"575_CR23","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413\u201324.","journal-title":"N Engl J Med"},{"issue":"20","key":"575_CR24","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","volume":"382","author":"PW Armstrong","year":"2020","unstructured":"Armstrong PW, Pieske B, Anstrom KJ, et al. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med. 2020;382(20):1883\u201393.","journal-title":"N Engl J Med"},{"issue":"36","key":"575_CR25","doi-asserted-by":"publisher","first-page":"3741","DOI":"10.1093\/eurheartj\/ehab499","volume":"42","author":"AM Jackson","year":"2021","unstructured":"Jackson AM, Jhund PS, Anand IS, et al. Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction. Eur Heart J. 2021;42(36):3741\u201352.","journal-title":"Eur Heart J"},{"issue":"24","key":"575_CR26","doi-asserted-by":"publisher","first-page":"2952","DOI":"10.1016\/j.jacc.2017.04.041","volume":"69","author":"P Hao","year":"2017","unstructured":"Hao P, Jiang F, Cheng J, Ma L, Zhang Y, Zhao Y. Traditional Chinese medicine for cardiovascular disease: evidence and potential mechanisms. J Am Coll Cardiol. 2017;69(24):2952\u201366.","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"575_CR27","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/j.jacc.2013.05.035","volume":"62","author":"X Li","year":"2013","unstructured":"Li X, Zhang J, Huang J, et al. A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the effects of qili qiangxin capsules in patients with chronic heart failure. J Am Coll Cardiol. 2013;62(12):1065\u201372.","journal-title":"J Am Coll Cardiol"},{"key":"575_CR28","unstructured":"Notice on printing and distributing the requirements for the work of the construction of the major clinical drug evaluation technology platform for major new drugs. 2019. http:\/\/www.nhc.gov.cn\/qjjys\/s3593k\/201901\/f4b2ff724a564b35964b296b427b9002.shtml. Accessed 2 Apr 2022"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-023-00575-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-023-00575-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-023-00575-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,6]],"date-time":"2023-05-06T05:26:45Z","timestamp":1683350805000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-023-00575-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,14]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["575"],"URL":"https:\/\/doi.org\/10.1007\/s40256-023-00575-8","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,14]]},"assertion":[{"value":"15 February 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was supported by Study on the Relationship between China's Economic and Social Development and the Development of Health Undertakings, National Health Committee, China, 2020.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publish"}},{"value":"The datasets generated and\/or analyzed during the current study cannot be shared externally.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}},{"value":"JH had full access to all the data in the study and takes responsibility for the accuracy of the data analysis. JH drafted the manuscript. CL and CW developed the search strategy and revised the manuscript. CL, YL, and CH reviewed the data manually. WL, SL, and LZ reviewed the manuscript and provided critical comments. CL and JL provided many helpful comments and made great contributions to the revised manuscript. WH was responsible for the study design, supervision, and revision of the manuscript.","order":10,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}